Chicago, Illinois 60614


This study uses a double autologous peripheral blood stem cell rescue (PBSC) following dose-intensive chemotherapy for the treatment of high-risk pediatric solid tumors.

Study summary:

Significant advances have been made in recent years in the treatment of solid tumors of childhood. However, much of the improvement in survival has been made in low stage and localized disease. Of significance is the fact that the improvements have come in up-front remission rates without translation into significantly high event-free survival(EFS) or overall survival (OS). This is despite the fact that these tumors as a whole are largely chemotherapy responsive. Recent advances in the understanding of the biology of hematopoeitic stem cells have driven the design of treatment regimens that allow for dose intensification without unacceptable hematologic toxicity. Protocol development has focused on active agents that have a broad range between hematologic and non-hematologic toxicities. This study uses a double autologous peripheral blood stem cell rescue (PBSC) following dose-intensive chemotherapy for the treatment of high-risk pediatric solid tumors. This study utilizes PBSC to limit the risk of tumor cell contamination while retaining prompt hematologic recovery from these highly intensified treatments.


Inclusion Criteria: - Malignant Diseases: - Ewing's sarcoma/PNET: - CR1 - Metastatic disease at diagnosis, tumor volume > 100 ml, pelvic bone primary - CR2 - Locally recurrent disease - Soft tissue sarcoma - CR1 - Metastatic disease at diagnosis or locally advanced disease where local control is suboptimal (i.e., inability to provide radiation therapy due to extent of disease). - CR2 - Locally recurrent disease (VGPR2 acceptable) - Hepatoblastoma: - VGPR1 - Patients with metastatic disease at diagnosis who have a persistently elevated alpha FP, or unresectable primary as a way of converting to resectable. - CR2/VGPR2 - Hodgkin's Disease: - VGPR1 - Progression on primary therapy/Refractory disease - CR2/VGPR2 - Germ Cell Tumor: - CR2/VGPR2 - recurrent disease - Wilms Tumor: - CR2/VGPR2 - recurrent disease - IRB approved signed written informed consent by patient and/or their legally authorized guardian. - Patients 21 years of age or younger at initial diagnosis, with older patients considered individually for primary pediatric disease diagnosis. - Adequate central venous access (double lumen CVL or 2 single lumen PCVC). - Adequate PBSC harvests with a minimum of 2.0 x 108 MNC/kg available for each PBSC rescue. - Organ Function: - Platelets > 50,000/ml - SGOT < 10 x upper limits of normal - Creatinine < 1.5 x normal baseline - Normal cardiac function in accordance with institutional policies - Normal pulmonary function in accordance with institutional policies. - Physiologic status: - No active infections - Adequate performance status as measured by Karnofsky (> 70%) or Lansky scale (> 60%) as appropriate for age. - Bone Marrow Status - No evidence of morphologic involvement with tumor at the time of transplant Off Study Criteria: - Severe toxicity. Contact the Study Coordinator immediately and complete Adverse Reaction Form. - Disease progression or relapse prior to PBSC #1 or between PBSC rescue # 1 and #2. - Inability to collect adequate numbers of PBSC for successful transplantation. - Patient or parent/guardian refusal to remain on study.



Primary Contact:

Principal Investigator
Morris Kletzel, M.D.
Children's Memorial Hospital

Morris Kletzel, M.D.
Phone: 773.880.4000 ext. 4564

Backup Contact:

Meredith Marshall
Phone: 773-880-3459

Location Contact:

Chicago, Illinois 60614
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.